UK-based company 32Co expands its Sleep Centre network, aimed at addressing the increasing sleep disorder predicament nationwide.
In a groundbreaking move, London-based healthtech company 32Co is set to launch a nationwide network of sleep centres, named 'Aerox Sleep Centres', this summer. This expansion marks the company's second foray into healthcare, following their successful improvement of patient access to specialist orthodontic services.
The new sleep centres will significantly improve access to Mandibular Advancement Devices (MADs), a non-invasive treatment for Obstructive Sleep Apnoea (OSA) and snoring. MADs, which have been found to have 25% higher adherence compared to Continuous Positive Airway Pressure (CPAP) machines, offer similar improvements in Excessive Daytime Sleepiness (EDS) and Quality of Life (QoL).
The intrusive nature of CPAP machines often causes patients to stop treatment due to discomfort, claustrophobia, and travel difficulties. MADs, on the other hand, are the only effective treatment against snoring with limited scientifically-backed alternatives until now.
The expansion is supported by Professor Ama Johal, a world-renowned Dental Sleep Medicine expert and Clinical Lead at 32Co. Professor Johal believes that the unobtrusive MADs will benefit many people, with 1 in 4 people in the UK snoring or snoring problematically, potentially leading to chronic sleep disruption.
The sleep centres will initially be located in London, Manchester, Edinburgh, and Bristol, with further centres to launch nationwide. They will focus on treating patients with mild to moderate OSA and problematic snoring.
In pre-pilot trials, Aerox Sleep Centres and MADs have helped hundreds of patients improve their sleep. John, 69, from Manchester, stated he would sleep downstairs with the dog if his device broke, and would be extremely disappointed. 32Co has also reported that 80% of the patients they spoke to admitted they would be very disappointed if they could no longer use their sleep devices.
OSA is a disorder that causes breathing to stop during sleep, and it might affect around 8 million people aged 30-69 in the UK according to Lancet (2020). The condition is linked with serious medical conditions, with prevalence as high as 40% to 80% in patients with hypertension, heart failure, coronary artery disease, pulmonary hypertension, atrial fibrillation, and stroke.
Helen, 64, from London, and Michael, 58, from the same city, expressed their belief that many people would benefit from the unobtrusive MADs. They believe that more people suffer from snoring than realize.
While the current status of 32Co’s nationwide network of sleep centres cannot be confirmed due to limited available information, the company's success in the orthodontic sector and the promising results of MADs offer a promising outlook for those suffering from OSA and snoring.
- The healthtech company, 32Co, is set to launch a network of sleep centers, 'Aerox Sleep Centres', this summer, focusing on treating patients with mild to moderate Obstructive Sleep Apnoea (OSA) and problematic snoring.
- MADs, a non-invasive treatment for OSA and snoring, will be significantly improved in access through these sleep centers, as they have shown 25% higher adherence compared to Continuous Positive Airway Pressure (CPAP) machines.
- The unobtrusive nature of MADs, the only effective treatment against snoring with limited scientifically-backed alternatives, is believed by Professor Ama Johal, a Dental Sleep Medicine expert and Clinical Lead at 32Co, to benefit many people, as 1 in 4 people in the UK snore or snore problematically.
- The success of 32Co in the orthodontic sector and the promising results of MADs in pre-pilot trials offer a promising outlook for those suffering from OSA and snoring, as they might be helping to manage chronic sleep disruption and related medical conditions like hypertension, heart failure, coronary artery disease, and stroke.
